Product
Pyronaridine-artesunate
Aliases
Pyronaridine-artesunate (Pyramax) 360 mg/120 mg, Pyronaridine-artesunate (Pyramax) 720 mg/240 mg
3 clinical trials
2 indications
Indication
MalariaIndication
COVID-19Clinical trial
Phase IIa Proof of Concept, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Combination M5717 Plus Pyronaridine Administered Once Daily for 1 or 2 Days to Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)Status: Recruiting, Estimated PCD: 2024-09-18
Clinical trial
Phase 1, Open-label, Cross-over Study to Investigate the Relative Bioavailability of Pyramax (Pyronaridine-artesunate) in Tablet and Granule Formulations, in Healthy VolunteersStatus: Completed, Estimated PCD: 2013-10-01
Clinical trial
Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina FasoStatus: Completed, Estimated PCD: 2022-11-01